• Login
Read without ads. Subscribe KOMPAS.com+

Indonesia to Get 140 Million Doses of Sinovac Covid-19 Bulk Vaccine Soon

17 February 2021, 17:25 WIB


JAKARTA, KOMPAS.com – Indonesia’s state-owned pharmaceutical company Bio Farma will produce more Covid-19 vaccine after receiving the bulk vaccine from China’s Sinovac shortly.

“We have made an agreement with Sinovac who will send 140 million doses of Covid-19 bulk vaccine based on the agreed timeline,” said Bio Farma president director Honesti Basyir in a press conference on Tuesday, February 16.

Also read: BPOM Greenlights Sinovac Covid-19 Vaccine Manufactured by Bio Farma

This announcement was made following the production of 13 million doses of ready-to-use vaccine by Bio Farma. Previously, the company received 15 million doses of bulk vaccine from Sinovac on January 12.

"This achievement will certainly be an encouragement for us to maintain the stability of the supply of the covid-19 vaccine," said Honesti.

Also read: Indonesian Traditional Market Traders to Get Covid-19 Vaccine in Stages

He further added with the issuance of the Emergency Use Authorization (EUA) for the Covid-19 vaccine, Bio Farma would distribute 7.5 million doses of ready-to-use vaccine for the second phase of the mass vaccination program.

“The 7.5 million doses will be provided for non-healthcare workers,” he said.

(Writer: Haryanti Puspa Sari | Editor: Diamanty Meiliana)

Source: https://nasional.kompas.com/read/2021/02/16/15012861/bio-farma-sudah-agreement-140-juta-dosis-bahan-baku-akan-segera-dikirim?page=2.

 



Comment wisely and responsibly. Comments are entirely the responsibility of the commentator as regulated in the ITE Law
Report
Thank You! We have received your report. We will remove comments that conflict with the Community Guidelines and the ITE Law.
Read without ads. Subscribe KOMPAS.com+
Read without ads. Subscribe KOMPAS.com+
Read without ads. Subscribe KOMPAS.com+
Close Ads

Copyright 2008 - 2026 PT. Kompas Cyber Media (Kompas Gramedia Digital Group). All Rights Reserved.

View